2026 Kenneth D. Bloch Memorial Lecture in Vascular Biology – Saumya Das, MD, PhD, MSc

Saumya Das, MD, PhD, MSc

Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Saumya Das, MD, PhD, is Professor of Medicine at Harvard Medical School, a faculty member of the Cardiac Arrhythmia Service and the co-director of the Inherited Arrhythmic Clinic at Massachusetts General Hospital. His research has focused on signaling pathways in electrical and structural remodeling in models of heart failure and cardiometabolic disease with a focus on extracellular vesicles and their cargo RNAs as biomarkers and mediators of intercellular signaling.

Das completed his undergraduate training at Harvard College, graduating summa cum laude in biology. He completed his MD-PhD training at Harvard Medical School (in the Health Sciences and Technology pathway) with his PhD in neurobiology. Following that, Das completed his residency in internal medicine, along with fellowship training in cardiovascular disease and clinical cardiac electrophysiology, all at MGH.

He has been the lead PI of several National Center for Advancing Translational Sciences grants to discover and validate RNA biomarkers of cardiac arrhythmias and heart remodeling in heart failure as part of the NIH Extracellular RNA Communication Consortium, where he has served as a cochair of the steering committee. He was inducted into the American Society of Clinical Investigation in 2020 and received an NIH EIA award (R35). He has served as a principal investigator on several American Heart Association strategic network grants, is on the advisory board for the American Association of Extracellular Vesicles and was the meeting chair for the 2023 Annual Scientific Sessions for AAEV. He is the current chair of the NHLBI CCHS Study Section.

Work in his laboratory has led to several patents. He is a cofounder of Thryv Therapeutics and Switch Therapeutics, which seek to advance novel therapies for inherited arrhythmia syndromes, heart failure and cardiac hypertrophy, with assets in phase 2 trials.